China Metastatic Liver Cancer Clinical Registry Cohort Database

NCT07602504 | Recruiting

• 1 other identifier: 2025KY534
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 3

Brief Summary

This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.

Conditions

Liver Metastases; Metastases to Liver; Liver Cancer; Neoplasms; Liver Diseases; Colorectal Cancer Metastatic

Keywords

Liver Metastases; Metastatic Colorectal Cancer

Outcome Measures

Primary Outcomes (1)

• Overall Survival

  The time interval from the date of initial diagnosis (or date of enrollment/surgery) to the date of death from any cause.

  Up to 10 years

Secondary Outcomes (2)

• Progression-Free Survival

  Up to 10 years

• Treatment-Related Adverse Events

  Within 90 days post-treatment

Interventions

Standard of Care for Metastatic Liver Cancer PROCEDURE

In this observational patient registry, no specific interventional procedure is assigned by the investigators. Patients included in the database receive standard clinical management and treatments for metastatic liver cancer according to current clinical guidelines and physician's discretion. These procedures may include hepatectomy, ablation, transarterial chemoembolization (TACE), systemic chemotherapy, targeted therapy, or immunotherapy. This registry aims to evaluate the real-world effectiveness and safety of these standard interventions.

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This registry targets adult patients with histologically or radiologically confirmed metastatic liver cancer. The population encompasses patients undergoing various standard clinical management strategies, including surgical resection, local ablation, transarterial chemoembolization (TACE), and systemic therapies (chemotherapy, targeted therapy, or immunotherapy).

You may qualify if:

• Patients with histologically or radiologically confirmed metastatic liver cancer.
• Age ≥ 18 years.
• Patients who have voluntarily signed the informed consent form.
• Patients with complete baseline clinical data.

You may not qualify if:

• Patients with primary liver cancer (e.g., hepatocellular carcinoma).
• Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.
• Patients who have previously participated in other interventional clinical trials.
• Patients with severe cognitive disorders or communication barriers that prevent informed consent.
• Patients with incomplete or missing key clinical data.

Sponsors & Collaborators

• Anhui Provincial Hospital: lead

Study Sites (3)

The First Affiliated Hospital of Bengbu Medical University

Bengbu, Anhui, 230001, China

NOT YET RECRUITING

The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

Hefei, Anhui, 230001, China

RECRUITING

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266003, China

RECRUITING

MeSH Terms

Conditions

Liver Neoplasms; Neoplasms; Liver Diseases; Colorectal Neoplasms

Interventions

Standard of Care

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Intestinal Neoplasms; Gastrointestinal Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Quality Indicators, Health Care; Quality of Health Care; Health Services Administration; Health Care Quality, Access, and Evaluation

Central Study Contacts

Jizhou Wang, MD PhD

CONTACT

+86 13836135864; wangjoe@ustc.edu.cn

Lianxin Liu, MD PhD

CONTACT

+86 13845159888; liulx@ustc.edu.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 10 Years
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 16, 2026
• First Posted: May 22, 2026
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): May 31, 2031
• Study Completion (Estimated): May 31, 2036
• Last Updated: May 22, 2026

Record last verified: 2026-05

Locations

CN (3)